Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cellebrite DI (CLBT) EBITDA (2020 - 2025)

Historic EBITDA for Cellebrite DI (CLBT) over the last 6 years, with Q3 2025 value amounting to $20.0 million.

  • Cellebrite DI's EBITDA fell 9037.69% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.4 million, marking a year-over-year decrease of 2079.53%. This contributed to the annual value of $99.4 million for FY2024, which is 6034.76% up from last year.
  • According to the latest figures from Q3 2025, Cellebrite DI's EBITDA is $20.0 million, which was down 9037.69% from $21.2 million recorded in Q2 2025.
  • Cellebrite DI's 5-year EBITDA high stood at $207.9 million for Q3 2024, and its period low was -$70.9 million during Q1 2024.
  • In the last 5 years, Cellebrite DI's EBITDA had a median value of $7.4 million in 2023 and averaged $15.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 45191.64% in 2022, then soared by 525307.4% in 2023.
  • Over the past 5 years, Cellebrite DI's EBITDA (Quarter) stood at $4.3 million in 2021, then soared by 90.04% to $8.2 million in 2022, then tumbled by 270.95% to -$14.0 million in 2023, then skyrocketed by 249.68% to $20.9 million in 2024, then decreased by 4.44% to $20.0 million in 2025.
  • Its EBITDA stands at $20.0 million for Q3 2025, versus $21.2 million for Q2 2025 and $16.2 million for Q1 2025.